 Gene Expression Regulation, Neoplastic
"Gene Expression Regulation, Neoplastic" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.
| Descriptor ID |
D015972
|
| MeSH Number(s) |
G05.355.315.370
|
| Concept/Terms |
Gene Expression Regulation, Neoplastic- Gene Expression Regulation, Neoplastic
- Regulation, Gene Expression, Neoplastic
- Neoplastic Gene Expression Regulation
- Regulation of Gene Expression, Neoplastic
|
Below are MeSH descriptors whose meaning is more general than "Gene Expression Regulation, Neoplastic".
Below are MeSH descriptors whose meaning is more specific than "Gene Expression Regulation, Neoplastic".
This graph shows the total number of publications written about "Gene Expression Regulation, Neoplastic" by people in this website by year, and whether "Gene Expression Regulation, Neoplastic" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1990 | 0 | 1 | 1 | | 1994 | 0 | 1 | 1 | | 1995 | 2 | 0 | 2 | | 1996 | 0 | 2 | 2 | | 1997 | 1 | 1 | 2 | | 1998 | 1 | 0 | 1 | | 1999 | 3 | 0 | 3 | | 2000 | 1 | 1 | 2 | | 2001 | 1 | 1 | 2 | | 2002 | 2 | 3 | 5 | | 2003 | 3 | 3 | 6 | | 2004 | 4 | 1 | 5 | | 2005 | 6 | 3 | 9 | | 2006 | 4 | 3 | 7 | | 2007 | 8 | 3 | 11 | | 2008 | 3 | 7 | 10 | | 2009 | 7 | 10 | 17 | | 2010 | 3 | 14 | 17 | | 2011 | 5 | 13 | 18 | | 2012 | 8 | 14 | 22 | | 2013 | 6 | 10 | 16 | | 2014 | 10 | 10 | 20 | | 2015 | 9 | 17 | 26 | | 2016 | 4 | 6 | 10 | | 2017 | 5 | 8 | 13 | | 2018 | 1 | 3 | 4 | | 2019 | 2 | 4 | 6 | | 2020 | 0 | 1 | 1 | | 2021 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Gene Expression Regulation, Neoplastic" by people in Profiles.
-
Haye K, Babu S, Oblein L, Gupta R, Akalin A, Escobar-Hoyos LF, Shroyer KR. Keratin 17 Expression Predicts Poor Clinical Outcome in Patients With Advanced Esophageal Squamous Cell Carcinoma. Appl Immunohistochem Mol Morphol. 2021 02 01; 29(2):144-151.
-
Das A, Martinez Santos JL, Alshareef M, Porto GBF, Infinger LK, Vandergrift WA, Lindhorst SM, Varma AK, Patel SJ, Cachia D. In Vitro Effect of Dovitinib (TKI258), a Multi-Target Angiokinase Inhibitor on Aggressive Meningioma Cells. Cancer Invest. 2020 Jul; 38(6):349-355.
-
Nama S, Muhuri M, Di Pascale F, Quah S, Aswad L, Fullwood M, Sampath P. MicroRNA-138 is a Prognostic Biomarker for Triple-Negative Breast Cancer and Promotes Tumorigenesis via TUSC2 repression. Sci Rep. 2019 09 03; 9(1):12718.
-
Moreno Leon L, Gautier M, Allan R, Ilié M, Nottet N, Pons N, Paquet A, Lebrigand K, Truchi M, Fassy J, Magnone V, Kinnebrew G, Radovich M, Cheok MH, Barbry P, Vassaux G, Marquette CH, Ponzio G, Ivan M, Pottier N, Hofman P, Mari B, Rezzonico R. The nuclear hypoxia-regulated NLUCAT1 long non-coding RNA contributes to an aggressive phenotype in lung adenocarcinoma through regulation of oxidative stress. Oncogene. 2019 11; 38(46):7146-7165.
-
Goyal A, Patel S, Goyal K, Morgan EA, Foreman RK. Variable loss of CD30 expression by immunohistochemistry in recurrent cutaneous CD30+ lymphoid neoplasms treated with brentuximab vedotin. J Cutan Pathol. 2019 Nov; 46(11):823-829.
-
Khurana L, ElGindi M, Tilstam PV, Pantouris G. Elucidating the role of an immunomodulatory protein in cancer: From protein expression to functional characterization. Methods Enzymol. 2019; 629:307-360.
-
Di Nunno V, Frega G, Santoni M, Gatto L, Fiorentino M, Montironi R, Battelli N, Brandi G, Massari F. BAP1 in solid tumors. Future Oncol. 2019 Jun; 15(18):2151-2162.
-
Wang JC, Chen C, Kundra A, Kodali S, Pandey A, Wong C, Cheung T, Gotlieb V, Joseph G, Tribie S. Programmed Cell Death Receptor (PD-1) Ligand (PD-L1) expression in Philadelphia chromosome-negative myeloproliferative neoplasms. Leuk Res. 2019 04; 79:52-59.
-
Ng SY, Yoshida N, Christie AL, Ghandi M, Dharia NV, Dempster J, Murakami M, Shigemori K, Morrow SN, Van Scoyk A, Cordero NA, Stevenson KE, Puligandla M, Haas B, Lo C, Meyers R, Gao G, Cherniack A, Louissaint A, Nardi V, Thorner AR, Long H, Qiu X, Morgan EA, Dorfman DM, Fiore D, Jang J, Epstein AL, Dogan A, Zhang Y, Horwitz SM, Jacobsen ED, Santiago S, Ren JG, Guerlavais V, Annis DA, Aivado M, Saleh MN, Mehta A, Tsherniak A, Root D, Vazquez F, Hahn WC, Inghirami G, Aster JC, Weinstock DM, Koch R. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018 05 22; 9(1):2024.
-
Choi J, Lee K, Ingvarsdottir K, Bonasio R, Saraf A, Florens L, Washburn MP, Tadros S, Green MR, Busino L. Loss of KLHL6 promotes diffuse large B-cell lymphoma growth and survival by stabilizing the mRNA decay factor roquin2. Nat Cell Biol. 2018 05; 20(5):586-596.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|